VOLUME 9 - ISSUE 1 | September 2020COVER STORY
The Ins and Outs of Clinical Trials
The process, the outcomes, and the laboratory perspective
Technology
|
Clinical Labs Turn to Automation to Solve Personnel Shortages
Automating workflows allows labs to do more with less
|
Custom Manufacturing: Translating Research into Products and Assays
Researchers who develop clinical products and assays often lack the experience, infrastructure, and quality systems to get into the market
|
Infectious Disease Testing at the Point of Care
The biomarkers and technologies that make rapid, on-site diagnosis possible
|
POCT for Blood Donation: What Are the Risks and Benefits?
Convenience must be balanced with a level of accuracy and reliability that ensures donations do not harm volunteers or patientsInsight
|
Clinical Labs Turn to Automation to Solve Personnel Shortages
Automating workflows allows labs to do more with less
|
Dealing with Vitamin D Assay Variability
Inconsistencies among vitamin D testing methods highlight the need for standardization across labs
|
A New Generation of Malaria Vaccines
Promising results from the first in-human trials of genetically engineered malaria vaccinesManagement
|
Why Greater Diversity is Needed in Genomic Research
Including participants of diverse ancestries in genome-wide association studies improves disease risk prediction, diagnosis, and development of treatmentsRegulatory
|
When is it Ethical to Stop a Clinical Trial?
The benefits of ending a trial early must be weighed carefully against the risksBusiness
|
Regional Labs Get in the Clinical Trial Game
Mid-sized labs are joining larger commercial labs in the research testing spaceThought Leadership
|
Innovations in Clinical Trial Design
?????Matthew M. Laughon, MD, MPH is a professor at the University of North Carolina (UNC) at Chapel Hill in thedepartment of pediatrics.
